OBJECTIVES: Parkinson disease (PD) is a chronic progressive disorder that causes significant disability and reduces quality of life (QOL). In Europe the prevalence of PD is 160/100 000 among those aged 65 and older, and annual direct cost associated to this disease ranging from 5163€ to 9975€ per patient. No cure is available to stop the disease, and an American study shows that a patient education program reduced disease progression, improved health confidence, reduced medication and decreases physician visits. The aim of this study is to assess the cost-utility of a therapeutic education program vs. traditional care in  PD patients. METHODS: A total of 120 patients of both sexes, under medication and meeting the criteria of the United Kingdom Parkinson’s Disease Society were recruited from two neurology departments in University Hospital of Toulouse between 2008 and 2010. The primary outcome measure was the incremental cost-utility ratio of therapeutic education program vs. traditional care. The primary medical outcome was the difference between baseline and one year SF-36 v1 score transformed to utility trough a utility function provided by Qualitymetrics®. This prospective economic analysis adopted the health care payer’s perspective and take into account direct medical and non-medical costs. RESULTS: Forty-five patients were excluded because they were not found on social health insurance database. Costs and utility were adjusted on age, sex and disease duration. Annual adjusted cost per patient was respectively 6633, 34€ (sd=1250.15) in 34 patients and 6941, 17€ (sd=1125.51) in 41 patients for traditional care group and therapeutic education program group (p=0.86). Adjusted difference of utility was -0,020 (sd=0.019) and 0.019 (sd=0.017) for traditional care group and therapeutic education program group respectively (p=0.14). Incremental cost-utility adjusted ratio was 7880.25/QALY. CONCLUSIONS: Therapeutic education program for Parkinson disease patients is cost-effective. Nevertheless, these results should be confirmed with multicenter prospective studies assessing medical and economic consequences of these strategies.